India Needs Innovative Strategies to Eliminate TB
Health · Saturday, 6 June 2026
ICMR's PreVenTB trial shows indigenous vaccines provide protection against tuberculosis.
Quick highlights
- ICMR's trial shows VPM1002 and Immuvac vaccines are effective.
- TB remains a leading infectious killer globally.
- Need for improved diagnostics and nutritional support.
- Focus on targeted vaccination strategies.
Context
Recent data from ICMR's PreVenTB trial reveals significant vaccine efficacy.
Key Facts
VPM1002 shows 50.4% efficacy against extrapulmonary TB.
Significance
Addressing TB is crucial for public health in India.
Challenges / Way Forward
Need for comprehensive strategies to tackle TB.
Exam Angle
Relevant for health and disease control topics in UPSC.
Remember this
- TB is a leading infectious killer globally.
- ICMR's trial involved 12,700 participants.
- VPM1002 offers significant protection for children.
- Need for innovative TB elimination strategies.
More from Saturday, 6 June 2026
- GDP Growth Estimated at 7.7% in FY 2025–26
- The Power of Mangroves Over Seawalls
- The Jan Samarth Portal
- Panchayat Advancement Index Wins Gold Recognition at National e-Governance Awards 2026
- Government Announces Measures to Deepen the G-Sec Market and Facilitate Greater Foreign Portfolio Investment (FPI)
- India Lodges Protest Over Pakistan's Planned Elections in Gilgit-Baltistan